-+ 0.00%
-+ 0.00%
-+ 0.00%

SAVARA: FDA's review of SAVARA's application for moxestine bioproduct licensing is ongoing; no revised date of action has been provided.

Zhitongcaijing·11/20/2026 13:33:20
Listen to the news
SAVARA: FDA's review of SAVARA's application for moxestine bioproduct licensing is ongoing; no revised date of action has been provided.